Yuki Katayama

1.1k total citations
30 papers, 619 citations indexed

About

Yuki Katayama is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yuki Katayama has authored 30 papers receiving a total of 619 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Yuki Katayama's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Research Studies (7 papers). Yuki Katayama is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Research Studies (7 papers). Yuki Katayama collaborates with scholars based in Japan. Yuki Katayama's co-authors include Koichi Takayama, Tadaaki Yamada, Junji Uchino, Yoshiko Kaneko, Yusuke Chihara, Nobuyo Tamiya, Masahiro Iwasaku, Takayuki Shimamoto, Keiko Tanimura and Takayuki Takeda and has published in prestigious journals such as The Journal of Immunology, Scientific Reports and Thorax.

In The Last Decade

Yuki Katayama

30 papers receiving 610 citations

Peers

Countries citing papers authored by Yuki Katayama

Since Specialization

Citations

This map shows the geographic impact of Yuki Katayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuki Katayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuki Katayama more than expected).

Fields of papers citing papers by Yuki Katayama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuki Katayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuki Katayama. The network helps show where Yuki Katayama may publish in the future.

Co-authorship network of co-authors of Yuki Katayama

This figure shows the co-authorship network connecting the top 25 collaborators of Yuki Katayama. A scholar is included among the top collaborators of Yuki Katayama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuki Katayama. Yuki Katayama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Initial AXL and MCL‐1 inhibition contributes to abolishing lazertinib tolerance in EGFR‐mutant lung cancer cells 2024 ·Cancer Science ·(unknown), Tadaaki Yamada, Yuki Katayama, (unknown), Ryo Sawada, (unknown), (unknown), Hayato Kawachi, (unknown), Naoya Nishioka, Kenji Morimoto, Masahiro Iwasaku, Mano Horinaka, Toshiyuki Sakai, Shinsaku Tokuda, Koichi Takayama	3
2	Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy 2024 ·Thoracic Cancer ·Kenji Morimoto, (unknown), Tadaaki Yamada, Toshihide Yokoyama, (unknown), Kazunari Tsuyuguchi, Takanori Kanematsu, Nobuyo Tamiya, Taisuke Tsuji, (unknown), Yuki Katayama, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama	2
3	Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer 2024 ·The Oncologist ·Yuki Katayama, Tadaaki Yamada, Ryo Sawada, Hayato Kawachi, Kenji Morimoto, Satoshi Watanabe, Kageaki Watanabe, Takayuki Takeda, Yusuke Chihara, Shinsuke Shiotsu, Makoto Hibino, Taishi Harada, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama	1
4	Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non‐small cell lung cancer 2024 ·Cancer Science ·(unknown), Masahiro Iwasaku, Toshifumi Doi, Takeshi Ishikawa, (unknown), Ryo Sawada, (unknown), Hayato Kawachi, Yuki Katayama, Naoya Nishioka, Kenji Morimoto, Shinsaku Tokuda, Tadaaki Yamada, Koichi Takayama	4
5	Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients 2024 ·Targeted Oncology ·Keisuke Onoi, Tadaaki Yamada, Kenji Morimoto, Hayato Kawachi, (unknown), Takayuki Takeda, (unknown), (unknown), Yusuke Chihara, Shinsuke Shiotsu, (unknown), Takahiro Yamada, Isao Hasegawa, Yuki Katayama, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama	1
6	Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer 2024 ·Cancer Letters ·(unknown), Tadaaki Yamada, Shinsaku Tokuda, Kenji Morimoto, Yuki Katayama, (unknown), (unknown), (unknown), Hayato Kawachi, Ryo Sawada, (unknown), Atsushi Osoegawa, Mano Horinaka, Toshiyuki Sakai, (unknown), (unknown), Seiji Yano, Koichi Takayama	11
7	TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study 2023 ·JTO Clinical and Research Reports ·Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Hiroyuki Fujii, (unknown), Keiko Tanimura, Takayuki Takeda, (unknown), Shinsuke Shiotsu, Yusuke Chihara, Osamu Hiranuma, Takahiro Yamada, (unknown), Taishi Harada, Isao Hasegawa, Akihiro Yoshimura, Masahiro Iwasaku, Shinsaku Tokuda, Young Hak Kim, Koichi Takayama	5
8	Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study 2023 ·Cancers ·Keiko Tanimura, Takayuki Takeda, Akihiro Yoshimura, Ryoichi Honda, (unknown), Shinsuke Shiotsu, (unknown), Yusuke Chihara, (unknown), (unknown), Yuki Katayama, Makoto Hibino, Tadaaki Yamada, Koichi Takayama	5
9	Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells 2023 ·Molecular Cancer Therapeutics ·(unknown), Tadaaki Yamada, Yuki Katayama, (unknown), Hayato Kawachi, (unknown), (unknown), Kenji Morimoto, Mano Horinaka, Toshiyuki Sakai, Yoshitaka Sekido, Shinsaku Tokuda, Koichi Takayama	5
10	Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study 2023 ·Targeted Oncology ·Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, (unknown), Nobuyo Tamiya, Yasuhiro Gotô, (unknown), Yusuke Chihara, (unknown), Yuki Katayama, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama	7
11	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells 2022 ·Cancer Medicine ·Yuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, (unknown), Naoya Nishioka, Kenji Morimoto, Keiko Tanimura, Yoshie Morimoto, Masahiro Iwasaku, Mano Horinaka, Toshiyuki Sakai, Kenji Kita, Seiji Yano, Koichi Takayama	5
12	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer 2021 ·Cancer Letters ·Keiko Tanimura, Tadaaki Yamada, Mano Horinaka, Yuki Katayama, (unknown), Kenji Morimoto, Takayuki Nakano, Shinsaku Tokuda, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Kazue Yoneda, Seiji Yano, Toshiyuki Sakai, Koichi Takayama	12
13	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients 2020 ·Medical Oncology ·Kenji Morimoto, Tadaaki Yamada, (unknown), Yuki Katayama, Satomi Tanaka, (unknown), Noriya Hiraoka, (unknown), Takayuki Takeda, Keisuke Onoi, Yusuke Chihara, (unknown), Takahiro Yamada, (unknown), Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Koichi Takayama	12
14	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer 2019 ·Cancer Medicine ·Tadaaki Yamada, (unknown), Yuki Katayama, Akihiro Yoshimura, Shinsuke Shiotsu, Satoshi Watanabe, Toshiaki Kikuchi, Kazuki Hirose, Yutaka Kubota, Yusuke Chihara, Taishi Harada, Keiko Tanimura, Takayuki Takeda, Nobuyo Tamiya, Yoshiko Kaneko, Junji Uchino, Koichi Takayama	78
15	Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer 2019 ·Thoracic Cancer ·Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Akihiro Yoshimura, Takayuki Takeda, Yusuke Chihara, Nobuyo Tamiya, Yoshiko Kaneko, Junji Uchino, Koichi Takayama	16
16	Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer 2019 ·Journal of Clinical Medicine ·Naoya Nishioka, Junji Uchino, (unknown), Yuki Katayama, Akihiro Yoshimura, (unknown), Keiko Tanimura, (unknown), Tatsuya Imabayashi, Yusuke Chihara, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama	75
17	Tumor Neovascularization and Developments in Therapeutics 2019 ·Cancers ·Yuki Katayama, Junji Uchino, Yusuke Chihara, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama	102
18	Oncolytic Reovirus Inhibits Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in a TLR3-Dependent Manner 2018 ·The Journal of Immunology ·Yuki Katayama, Masashi Tachibana, (unknown), (unknown), (unknown), (unknown), Kouji Kobiyama, Ken J. Ishii, Shizuo Akira, Hiroyuki Mizuguchi, Fuminori Sakurai	34
19	Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report 2018 ·Respiratory Medicine Case Reports ·Naoya Nishioka, Tadaaki Yamada, (unknown), (unknown), Yuki Katayama, Takayuki Nakano, (unknown), Nobuyo Tamiya, Yoshiko Kaneko, Junji Uchino, Koichi Takayama	7
20	Proteolytic Disassembly of Viral Outer Capsid Proteins Is Crucial for Reovirus-Mediated Type-I Interferon Induction in Both Reovirus-Susceptible and Reovirus-Refractory Tumor Cells 2015 ·BioMed Research International ·Yuki Katayama, (unknown), Masashi Tachibana, Hiroyuki Mizuguchi, Fuminori Sakurai	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact